Japan's SNBL Seeks Drug Maker Ties To Develop STAP Cells
This article was originally published in PharmAsia News
Executive Summary
Shin Nippon Biomedical Laboratories, a Japan-based preclinical services company, is seeking tie-ups with drug makers to create the newly discovered stimulus-triggered acquisition of pluripotency stem cells from monkey cells.